Indian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...

India and Brazil strengthened their strategic partnership during President Luiz Inacio Lula da Silva's state visit. Discussions covered bil...

Biocon Group reported a strong Q2 FY26 with a 20% year-on-year increase in operating revenue to Rs 4,296 crore, driven by biosimilars and g...

Biocon is set to launch generic versions of Wegovy in India and Canada, aiming for market entry by late 2026 or early 2027. This strategic ...

Biocon has partnered with Brazil-based Biomm SA for the commercialization of its diabetes drug, Semaglutide (gOzempic). Biocon will develop...

Chief Executive Officer and Managing Director, Siddharth Mittal, Biocon Ltd, said the association with Libbs Farmaceutica will help his com...

This partnership, which marks the entry of Biocon’s generic formulations into Latin America, builds upon a successful association with Libb...

Biosimilar trastuzumab, indicated for breast cancer treatment, has been co-developed by Biocon and Mylan.

The new Companies Act, which came in to effect on April 1, demands much more information as well as disclosures, making the entire process ...

Biocon is now exploring new partnerships with pharma companies for its biosimilars, or low-cost copies of biotechnology products.

Bangalore-based Biocon is planning to forge partnerships as well as leverage existing alliances to augment the access and penetration of it...